MAIA Biotechnology, Inc. Contracts & Agreements
58 Contracts & Agreements
- Business Finance (28 contracts)
- Business Operations (3)
- Human Resources (18)
- Intellectual Property (6)
- Uncategorized (3)
- Form of Securities Purchase Agreement (Filed With SEC on October 29, 2024)
- Form of Director Warrant (Filed With SEC on October 29, 2024)
- Form of Investor Warrant (Filed With SEC on October 29, 2024)
- Form of Amendment No. 1 to Common Stock Purchase Warrant (for April 25, 2024 Common Stock Purchase Warrants) (Filed With SEC on May 14, 2024)
- Form of Amendment No. 1 to Common Stock Purchase Warrant (for March 28, 2024 Common Stock Purchase Warrants) (Filed With SEC on May 14, 2024)
- Form of Amendment No. 1 to Common Stock Purchase Warrant (for March 14, 2024 Common Stock Purchase Warrants) (Filed With SEC on May 14, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on April 23, 2024)
- Form of Director Warrant (Filed With SEC on April 23, 2024)
- Form of Investor Warrant (Filed With SEC on April 23, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on March 26, 2024)
- Form of Warrant (Filed With SEC on March 26, 2024)
- DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 (Filed With SEC on March 21, 2024)
- Form of Investor Warrant (included as part of Exhibit 10.1) (Filed With SEC on March 13, 2024)
- At The Market Offering Agreement between MAIA Biotechnology, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on February 14, 2024)
- Form of Lock-Up Agreement (Filed With SEC on November 17, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on November 17, 2023)
- Form of Wainwright Warrant (Filed With SEC on November 17, 2023)
- Form of Warrant (Filed With SEC on November 17, 2023)
- Common Stock Purchase Warrant (Filed With SEC on November 16, 2023)
- Employment Agreement between Jeffrey Himmelreich and the Company, dated as of August 30, 2023 (Filed With SEC on November 15, 2023)
- Sales Agreement, dated September 1, 2023, by and between MAIA Biotechnology, Inc. and ThinkEquity LLC (Filed With SEC on September 1, 2023)
- Amendment No. 1 to MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (Filed With SEC on June 8, 2023)
- Form of Underwriting Agreement (including the form of Lock-Up Agreement) (Filed With SEC on June 8, 2023)
- Underwriting Agreement by and between the Company and the Representative dated April 24, 2023 (Filed With SEC on April 27, 2023)
- Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on April 20, 2023)
- Form of Underwriting Agreement (including the form of Lock-Up Agreement) (Filed With SEC on April 20, 2023)
- Form of Underwriting Agreement (including the form of Lock-Up Agreement) (Filed With SEC on February 6, 2023)
- Employment Agreement, dated as of September 16, 2022, between the Company and Sergei Gryaznov (Filed With SEC on September 21, 2022)
- Employment Agreement, dated as of September 16, 2022, between the Company and Joseph McGuire (Filed With SEC on September 21, 2022)
- Employment Agreement, dated as of September 16, 2022, between the Company and Mihail Obrocea (Filed With SEC on September 21, 2022)
- Employment Agreement, dated as of September 16, 2022, between the Company and Vlad Vitoc (Filed With SEC on September 21, 2022)
- Form of Director and Consultant Non-qualified Stock Option Award under 2021 Equity Incentive Plan (Filed With SEC on August 22, 2022)
- Form of Non-qualified Stock Option Award under 2021 Equity Incentive Plan (Filed With SEC on August 22, 2022)
- Form of Incentive Stock Option Award under 2021 Equity Incentive Plan (Filed With SEC on August 22, 2022)
- Form of Indemnification Agreement (Filed With SEC on August 1, 2022)
- Underwriting Agreement by and between the Company and the Representative dated July 27, 2022 (Filed With SEC on August 1, 2022)
- Form of Employee Stock Option Award Agreement under Amended & Restated 2020 Equity Incentive Plan (Filed With SEC on June 29, 2022)
- Form of Consulting Stock Option Award Agreement under Amended & Restated 2020 Equity Incentive Plan (Filed With SEC on June 29, 2022)
- Form of Compensatory Management Stock Option Award Agreement under Amended & Restated 2020 Equity Incentive Plan (Filed With SEC on June 29, 2022)
- Form of Director Stock Option Award under Amended & Restated 2020 Equity Incentive Plan (Filed With SEC on June 29, 2022)
- Form of Underwriting Agreement (including the form of Lock-Up Agreement) (Filed With SEC on June 29, 2022)
- Patent & Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical... (Filed With SEC on May 31, 2022)
- Form of Underwriting Agreement (including the form of Lock-Up Agreement) (Filed With SEC on May 31, 2022)
- Supply and Non-Exclusive License Agreement between the Company and Regeneron Pharmaceuticals, Inc. dated February 1, 2021 (Filed With SEC on May 31, 2022)
- Patent & Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical... (Filed With SEC on May 31, 2022)
- Form of Underwriting Agreement (including the form of Lock-Up Agreement) (Filed With SEC on April 29, 2022)
- Specimen Certificate representing shares of Common Stock (Filed With SEC on April 11, 2022)
- MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (Filed With SEC on April 11, 2022)
- MAIA Biotechnology, Inc. Amended & Restated 2020 Equity Incentive Plan (Filed With SEC on April 11, 2022)
- MAIA Biotechnology, Inc. 2018 Stock Option Plan (Filed With SEC on April 11, 2022)
- Form of Indemnification Agreement between the Company and each of its directors and executive officers (Filed With SEC on April 11, 2022)
- Employment Agreement between Mihail Obrocea and the Company signed August 2, 2022 (Filed With SEC on April 11, 2022)
- Employment Agreement between Joseph F. McGuire and the Company signed August 10, 2022 (Filed With SEC on April 11, 2022)
- Employment Agreement between Vlad Vitoc and the Company signed August 2, 2022 (Filed With SEC on April 11, 2022)
- Patent & Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical... (Filed With SEC on April 11, 2022)
- Patent & Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical... (Filed With SEC on April 11, 2022)
- Supply and Non-Exclusive License Agreement between the Company and Regeneron Pharmaceuticals, Inc. dated February 1, 2021 (Filed With SEC on April 11, 2022)
- Form of Warrant (Filed With SEC on April 11, 2022)
